NCT02726022View on ClinicalTrials.gov

A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels

CompletedOBSERVATIONAL
Enrollment

114

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

July 31, 2011

Study Completion Date

July 31, 2011

Conditions
Hepatitis C, Chronic
Interventions
DRUG

Peginterferon alfa-2a

As per treating physician discretion and according to summary of product characteristics.

DRUG

Ribavirin

As per treating physician discretion and according to summary of product characteristics.

Trial Locations (10)

11522

Athens

11526

Athens

11527

Athens

11528

Athens

12241

Aigaleo - Attiki

18454

Piraeus

18536

Piraeus

71100

Heraklion

115 27

Athens

546 42

Thessaloniki

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02726022 - A Quality of Life Study of Peginterferon-Alfa-2a Plus Ribavirin in Participants With Chronic Hepatitis C and Persistently Normal Alanine Transaminase (ALT) Levels | Biotech Hunter | Biotech Hunter